Trials / Completed
CompletedNCT00314743
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
A Study Evaluating the Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of aprepitant in preventing acute and delayed chemotherapy induced nausea and vomiting when administered in combination with intravenous or oral ondansetron and intravenous or oral dexamethasone in the autologous transplant setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ondansetron | |
| DRUG | Dexamethasone | |
| DRUG | Aprepitant |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2006-04-14
- Last updated
- 2013-05-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00314743. Inclusion in this directory is not an endorsement.